Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
flupirtine + paracetamol
- Development stage
- Unknown
- Lead developer
- Prospera Biotech
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
FLUPI MR-P is a fixed-dose combination product containing flupirtine and paracetamol (acetaminophen), marketed by Tabq Therapeutics. Flupirtine is a selective neuronal potassium channel opener (SNCPO) that acts as a non-opioid analgesic and muscle relaxant by facilitating the opening of KCNQ2/3 channels, thereby stabilizing the neuronal membrane potential. Paracetamol is a widely used analgesic and antipyretic that primarily acts through the inhibition of prostaglandin synthesis in the central nervous system. This combination is typically used for the management of acute and chronic pain, particularly when associated with muscle spasms. It is formulated as a modified-release (MR) tablet to provide sustained pain relief. Note: Flupirtine has been subject to regulatory restrictions and withdrawals in several regions, including Europe, due to risks of hepatotoxicity.
- Brand names
- FLUPI MR-P
- Other names
- Flupirtine maleate + ParacetamolFlupirtine + Acetaminophen
02
Targets
KCNQ3 (Potassium voltage-gated channel subfamily Q member 3)KCNQ2 (Potassium voltage-gated channel subfamily KQT member 2)PGHS-1 (Prostaglandin G/H Synthase 1)
Beyond the preview
Go deeper on flupirtine + paracetamol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on flupirtine + paracetamol.